A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers
NCT01659554
Terminated
The primary objective of this study is to investigate the feasibility, tolerability and safety of surgical debulking and resection with heated intraoperative chemotherapy (HIPEC) followed by repeated intraperitoneal chemotherapy for treatment of recurrent ovarian, primary peritoneal, and fallopian tube carcinomas.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/30/2017
Locations: Columbia University Medical Center, New York, New York
Conditions: Recurrent Ovarian Cancer, Fallopian Tube Cancer
Register for Updates
A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC
NCT00963807
Completed
This study is being done to compare a special type of Positron Emission Tomography (PET) scan with CT scan in patients with surgically removable lung cancer to see which method is more useful in measuring a response to treatment. A PET scan uses small amounts of radioactive material injected into the blood to show the internal workings of the body. In this study, we will use two radioactive materials: 18F-FLT (referred to as FLT) and 18F-FDG (referred to as FDG). FDG is used routinely in the sta... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
01/27/2017
Locations: Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland +1 locations
Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Register for Updates
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
NCT00571298
Completed
RATIONALE: After removal of visible cancer in the chest, chemotherapy drugs are used to kill or stop tumor cells from dividing, so that they stop growing or/and die. Cisplatin is currently used safely as in intra-operative treatment for malignant pleural mesothelioma. This study is aimed to determine if the addition of gemcitabine as a second intracavitary chemotherapy can be accomplished safely. PURPOSE: This is a Phase I trial to study the efficacy of combination chemotherapy consisting of ge... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/19/2017
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Malignant Pleural Mesothelioma
Register for Updates
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
NCT00002601
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose combination chemotherapy and peripheral stem cell transplantation in treating patients who have advanced or recurrent sarcoma.
Gender:
ALL
Ages:
Between 10 years and 55 years
Trial Updated:
01/18/2017
Locations: Cancer Center and Beckman Research Institute, City of Hope, Duarte, California
Conditions: Sarcoma
Register for Updates
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
NCT00949949
Completed
This randomized phase I trial is studying the side effects and best dose of everolimus, gemcitabine hydrochloride, and cisplatin in treating patients with unresectable solid tumors refractory to standard therapy. Drugs used in chemotherapy, such as everolimus, gemcitabine hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/11/2017
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Cholangiocarcinoma of the Gallbladder, Localized Gallbladder Cancer, Unresectable Gallbladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT00443261
Terminated
To evaluate the safety and toxicity of azacitidine (5-azacitidine, Vidaza®) and cisplatin combination in patients with squamous cell carcinoma of head and neck (SCCHN).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2017
Locations: Kansas City VA Medical Center, Kansas City, Missouri
Conditions: Squamous Cell Carcinoma
Register for Updates
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
NCT01383148
Terminated
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC). TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). TG4010 has been developed for use as an immunotherapy in cancer patients whose tumors express the MUC1 antigen. TG401... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2017
Locations: Mayo Clinic Arizona, Scottsdale, Arizona +71 locations
Conditions: Non-Small-Cell Lung Carcinoma
Register for Updates
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
NCT00003596
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known whether fluorouracil and mitomycin plus radiation therapy is more effective than fluorouracil and cisplatin plus radiation therapy for anal cancer. PURPOSE: This randomized phase III trial is studying fluorouracil and mitomycin plus radiation therapy to... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/30/2016
Locations: Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +484 locations
Conditions: Anal Cancer
Register for Updates
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00069953
Completed
RATIONALE: Drugs used in chemotherapy such as paclitaxel, fluorouracil, and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells PURPOSE: This phase II trial is studying how well combination chemotherapy followed by chemoradiotherapy, with or without surgery, works in treating patients with resectable locally advanced can... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/30/2016
Locations: Providence Saint Joseph Medical Center - Burbank, Burbank, California +96 locations
Conditions: Esophageal Cancer
Register for Updates
Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer
NCT00057785
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue, prevent or lessen mouth dryness, and may help patients live more comfortably. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of specialized radiation ther... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2016
Locations: Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama +16 locations
Conditions: Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
Register for Updates
Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma
NCT00002492
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining cisplatin and doxorubicin in treating patients who have soft tissue sarcoma.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/14/2016
Locations: Sylvester Cancer Center, University of Miami, Miami, Florida
Conditions: Sarcoma
Register for Updates
Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)
NCT00077051
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiosensitizing drugs, such as cytochlor and tetrahydrouridine, may make tumor cells more sensitive to radiation therapy. Drugs used in chemotherapy, such as cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Combining radiosensitizers with chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying... Read More
Gender:
ALL
Ages:
Between 21 years and 120 years
Trial Updated:
12/14/2016
Locations: University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Head and Neck Cancer
Register for Updates